Understanding Antihypertensive Medication Use after Living Kidney Donation through Linked National Registry and Pharmacy Claims Data
暂无分享,去创建一个
A. Garg | M. Schnitzler | D. Segev | D. Axelrod | K. Lentine | D. Brennan | J. Tuttle-Newhall | Huiling Xiao
[1] A. Garg,et al. Consistency of Racial Variation in Medical Outcomes Among Publicly and Privately Insured Living Kidney Donors , 2014, Transplantation.
[2] Mei-Cheng Wang,et al. Risk of end-stage renal disease following live kidney donation. , 2014, JAMA.
[3] Jackson T. Wright,et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). , 2014, JAMA.
[4] M. Schnitzler,et al. Understanding Medical Care of Transplant Recipients through Integrated Registry and Pharmacy Claims Data , 2013, American Journal of Nephrology.
[5] D. Segev,et al. Better understanding live donor risk through big data. , 2013, Clinical journal of the American Society of Nephrology : CJASN.
[6] D. Segev,et al. Health outcomes among non‐Caucasian living kidney donors: knowns and unknowns , 2013, Transplant international : official journal of the European Society for Organ Transplantation.
[7] M. Dorais,et al. Adherence to antihypertensive agents improves risk reduction of end-stage renal disease. , 2013, Kidney international.
[8] M. Stegall,et al. Demographic, Metabolic, and Blood Pressure Characteristics of Living Kidney Donors Spanning Five Decades , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[9] A. Garg,et al. Medical Outcomes in African American Live Kidney Donors: A Matched Cohort Study , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[10] B. Kasiske,et al. Living Kidney Donor Follow‐Up: State‐of‐the‐Art and Future Directions, Conference Summary and Recommendations , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[11] B. Schröppel,et al. When Good Intentions Are Not Enough: Obtaining Follow‐Up Data in Living Kidney Donors , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[12] T. Villines,et al. Cardioprotective Medication Use After Acute Myocardial Infarction in Kidney Transplant Recipients , 2011, Transplantation.
[13] C. Young,et al. Living Donor Nephrectomy: Understanding Long‐Term Risk in Minority Populations , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[14] M. Schnitzler,et al. Racial variation in medical outcomes among living kidney donors. , 2010, The New England journal of medicine.
[15] A. Garg,et al. Health insurance status of US living kidney donors. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[16] S. Jacobs,et al. A Study of Renal Outcomes in African American Living Kidney Donors , 2009, Transplantation.
[17] M. Schnitzler,et al. Transplant Outcomes and Economic Costs Associated with Patient Noncompliance to Immunosuppression , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[18] W. Weimar,et al. Long-term consequences of kidney donation. , 2009, The New England journal of medicine.
[19] A. Garg,et al. Cardiovascular Disease and Hypertension Risk in Living Kidney Donors: An Analysis of Health Administrative Data in Ontario, Canada , 2008, Transplantation.
[20] A. Garg,et al. Meta-Analysis: Risk for Hypertension in Living Kidney Donors , 2006, Annals of Internal Medicine.
[21] A. Lippman. Adherence to medication. , 2005, The New England journal of medicine.
[22] Daniel W. Jones,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.
[23] Sudha Seshadri,et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. , 2002, JAMA.
[24] M. Stenbeck,et al. Kidney donors live longer. , 1997, Transplantation.
[25] H. S. Lau,et al. Validation of pharmacy records in drug exposure assessment. , 1997, Journal of clinical epidemiology.
[26] Fred H. Wiman,et al. Recording of drug prescriptions in the county of Jämtland, Sweden , 1977, European Journal of Clinical Pharmacology.
[27] A. Hartmann,et al. Overall and cardiovascular mortality in Norwegian kidney donors compared to the background population. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[28] S. Oparil,et al. Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report , 2014 .
[29] M. Schnitzler,et al. Novel methods for tracking long-term maintenance immunosuppression regimens. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[30] Paul Grootendorst,et al. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. , 2003, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.
[31] G. Boethius. Recording of drug prescriptions in the county of Jämtland, Sweden. II. Drug exposure of pregnant women in relation to course and outcome of pregnancy. , 1977, European journal of clinical pharmacology.